Sterilizing and Bioburden Filter Risk Assessment in Vaccine Processes as part of QRM

Similar documents
Quality by Design in Critical Filtration Operations

Validation Needs for Sterilization by Aseptic Filtration

PROCESS VALIDATION ROCHAPON WACHAROTAYANKUN, PH.D.

Quality Risk Management

Advancements on implementation of single use technology in vaccine manufacturing

Validation of Sterilizing Grade Filters

PAT & Risk-Based Initiatives: Implementation Issues PDA New England - 8 th Dec Cliff Campbell B.E., C.Eng. CC&A Ltd., Cork, Ireland

GMP GUIDELINES. GMP Guides from Industry Organisations. FDA cgmp WHO GMP. cgmp Guide Drugs 21 CFR 210 GAMP. ISPE Technical Guides

Update to the Manufacturing Principles for Medicinal Products

Risk Based Validation. Why, How and with what tools?

Paradigm Change in Manufacturing Operations SM

Annex A2. Guidance on Process Validation Scheme for Aseptically Processed Products

Outsourcing - managing risks and opportunities over which you now have less control

Identification and Control of Critical Process Points Using Complementary Risk Assessments (corrected)

Preparing Your Aseptic Processing Facility for an FDA Inspection. Valerie Welter, Director Quality Bayer HealthCare March 10, 2014

Overview of Regulatory Requirements for API and Formulations

Application of ICH Q12 Tools and Enablers Post-Approval Lifecycle Management Protocols

Overview and Introduction Annex 1 Revision

Quality Assurance in Pharmaceutical and Biotech Industries as Per Regulatory Guidelines

Complaints Investigations Root Cause Analysis

Guidance for Industry Process Validation: General Principles and Practices; A Contract Manufacturing Organization's Approach

UNICEF s Quality Assurance System for Procurement of Finished Pharmaceutical Products

A Journey in Global PUPSIT Implementation with Benchmarking. PDA Midwest Event Oct 5th, 2017 Jeff Gaerke P.E.

EUROPEAN INDUSTRIAL PHARMACISTS GROUP. Guidance on CPD for QUALIFIED PERSONS

ICH Q10/WHO TRS A Regulatory Perspective

HISTORY AND MILESTONES

WHO guidelines on quality risk management

Quality Agreements with CMO s. Presented at ASQ Orange Empire Meeting May 13, 2014 By Luke Foo Sr. Director QA/QC Spectrum Pharmaceuticals

CGMP for 21 st Century : A Risk-based Approach (Quality by Design)

GMP Track 1 Day 2 Session 1 Vendor Assurance

Overview of Inspection Issues with Legacy Products

T H E P R O P O S A L F O R T H E Y E A R

GMP Manual. Contents. Contents (1) 1 Pharmaceutical Quality System (PQS) 2 Personnel

EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL. This document is for consultation until 11 December 2015

EFFECTIVE MANAGEMENT OF THE PROCESS VALIDATION LIFECYCLE VALIDATION MASTER PLAN DEVELOPMENT

UNICEF Quality Assurance in the procurement of medicines

For sterile products manufacturing, Lyoseal is an innovative technology. presented by Mr. Tony Bouzerar from BioCorp offers us detailed

Phase Appropriate GMPs for IMPs. Presented by: Karen S. Ginsbury For: IFF, October 31, Nov 02, 2017

MASTER PLANNING FOR VALIDATION

Introduction and Background

STERILE FILTRATION: PDA: A Global. Clarification Proposal Annex 1 Paragraph 113:

Deficiencies found in Inspections and QP Responsibilities

The Application of Pharmaceutical cgmp to Live Bacterial Products. James Harris Business Development Manager

PDA: A Global. Association. Contamination Control: Particles, Bio-contamination, Aseptic manufacturing. PDA Parenteral 2014 Munich Conference

COMPLIANCE WITH EU ANNEX 15: VALIDATION AND QUALIFICATION

Impact of EU GMPs on Australian GMP. Trevor Schoerie PharmOut

ICH Quality Implementation Working Group POINTS TO CONSIDER

INSPECTION OF BIOTECHNOLOGY MANUFACTURES

Library Guide: Active Pharmaceutical

Impacto de las Nuevas Tendencias Regulatorias en la Producción de Parenterales. Innovacion en Packaging Primario

Aseptic Process Validation

Risk Analysis: myths, confusions and real sense

Federal Institute for Drugs and Medical Devices ICH-Leitlinie Q 8 - Pharmaceutical Development die regulatorische Perspektive

Process Design Risk Management A Proactive Approach

Q8 Pharmaceutical Development

ISPE Baseline Pharmaceutical Engineering Guide for New and Renovated Facilities Volume 2: Oral Solid Dosage Forms (Revision) Executive Summary

Testo Expert Knowledge. The GxP Dictionary 1st edition. Definitions relating to GxP and Quality Assurance

Application of Quality Risk Management Tools for Cell Therapy Manufacturing

Good Manufacturing Practices Purpose and Principles of GMP. Tony Gould

Analytical and formulation attributes

Industry Perspective on PET Manufacturing Comparison of EU and US

Review Validation of aseptic processes for pharmaceuticals

Single-Use Final Fill: Benefits and Considerations

EU and FDA GMP Regulations: Overview and Comparison

EMPROVE For Raw and Starting Materials & For Filtration Devices and Single Use Systems. Jan Thomsen Warsaw, November 15 th, 2016

Quality Risk Management (QRM) of active pharmaceutical ingredients during transportation by using FMEA tools and methodology

Process Drift: When Do We Detect it? Richard L. Friedman Director, DMPQ CDER/Office of Compliance PQRI Process Drift Workshop December 1, 2010

GMP considerations when designing an API plant. Presented by Cameron Roberts, Senior Engineer 4 July, 2016

Webinar. The New EU-GMP Annex 1 draft Dupont. GOP-Innovations your Partner for Practical Training and e-learning. 8 June 2018

Guidelines for Process Validation of Pharmaceutical Dosage Forms

October 10, Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane, Rm Rockville, MD 20852

Process Validation (PV): Designing an Effective PV Program. Mike Porter Compliance Consultant Commissioning Agents Inc.

GMP Compliance. George Acevedo, CQV Senior Engineer M+W Singapore Pte. Ltd

References Concept. Principle. EU Annex 11 US FDA , (g), (i), 11 Orlando Lopez 2/15/11. Old Annex 11.

Contents. Contents (13) 1 Production (23)

2-2 Sterile Product Assessment. Satish Mallya Ph.D Training Workshop CPH, May 2015

Supersedes Division Name Revision No. 0 Export Division Page No. 1 of 9

How do you know the drug you are using is safe and effective?

Control Strategy. Implementation of ICH Q8, Q9, Q10

Lifecycle Product Quality Risk Management

LABORATORY COMPLIANCE

GMP Challenges to Global Pharma Companies

Quality Systems. Indian Pharmaceutical Alliance. Advanced GMP Workshops 2017

Gary Hartnett, Bausch & Lomb

Risk Management: FDA and Industry Experience. Dan Snider, Ph.D Vice President Morgantown RD Mylan Pharmaceuticals Inc.

Left to Our Own Devices Design Control & Risk Management Strategies for Combination Products

School of Pharmacy & Pharmaceutical Sciences QP Forum Thursday 16th April McGee Pharma International

Critical Quality Attributes for Biotechnology Products: A Regulatory Perspective

Regulatory Requirements & Recent Changes, including expectations for APIs & IMPs

GUIDE TO GOOD MANUFACTURING PRACTICE FOR MEDICINAL PRODUCTS

Enabling Improvement through the Product Lifecycle: Change Management within a PQS

ROLE OF ICH GUIDELINES IN PHARMACEUTICAL QUALITY RISK MANGAMENT- REVIEW

Paradigm Change in Manufacturing Operations SM

Subpart B Organization and Personnel, 21 CFR Responsibilities of the quality control unit.

Trinity College Dublin QP Forum 2017 Tuesday 25 th April

Application of enhanced process and product knowledge to facilitate the lifecycle

On behalf of the PHSS Pharmaceutical and Healthcare Sciences Society (UK).

Quality Risk Management

The IPEC Risk Assessment Guide for Pharmaceutical Excipients. Part 1 Risk Assessment for Excipient Manufacturers

Transcription:

Sterilizing and Bioburden Filter Risk Assessment in Vaccine Processes as part of QRM DCVMN Workshop, Hyderabad, 4-8 April 2016 G. Somasundaram Associate Director - Technology Management

Overview Key Regulatory Concerns Aseptic Processing Risks Some Risk Assessment Tools Examples of 3 Typical Schematics Risk Sources in Sterile Filtration Filter Categories Definitions References 2

Key Regulatory Concerns Efficacy / Strength Identity & Purity Safety Does the validated production process result in a material / residues that interfere with product efficacy or strength? Does the validated production process result in a material / residues that interfere with product purity? Does the validated production process result in a material / residues that are toxic to the patient? 3

Challenges of Aseptic Processing Drug Product Sterilizatio n Process Sterile DP Container Closure Sterilizatio n Process Sterilizatio n Process Sterile Containe r Sterile Closure Aseptic Processing Sterile Final Product Excipient Component Sterilizatio n Process Sterile Excipient Componen t Multiple sterilization processes optimized for the individual materials Higher potential risk of non-sterile product 4

Overall picture of Quality by design Implementing Quality by Design - Helen N. Winkle, FDA, Sept 2007 5

cgmp - Risk-Based Approach...the level of effort, formality and documentation of the quality risk management process is commensurate with the level of risk Chapter 1, EU GMP guide With the revision of the chapters on quality management in GMP Parts I and II quality risk management becomes an integral part of a manufacturer s quality system. PICS Annex 20 All manufacturing authorisation holders.. must have a system for QRM. Inspectors will review the QRM system as part of the Quality Systems section of the inspection GMP Frequently Asked Questions (MHRA) Article 12: The manufacturers should establish the management system of quality risk.... The evaluation of the risk to quality is based on scientific knowledge, experience with the process and ultimately links to the protection of the patient. Pharmaceutical Products GMP (Draft for Comment) China SFDA, Version 1, 12-Oct-2009 6

Example of Traditional vs. Science / Risk-based Approach to Validation Traditional Arbitrarily selecting three batches for initial validation (e.g., qualification batches) and typically for process changes Science and risk-based lifecycle Uses scientific rationale to determine number of batches / amount of data required Determines scope of validation by analyzing data and significance of change Uses statistical tools during development, initial validation, and process monitoring Considers all potential risk factors in designing process validation studies and so helps prioritize critical aspects and reduces effort on aspects that are not important Based on objective evaluation, we need to move from left to right. 7

ICH Q9 Links Risk of Process to Patient Design Opportunities to impact risk using quality risk management Process Materials Manufacturing Facilities Distribution Patient 8 G.- Claycamp, FDA, June 2006

Examples of Tools to Assess and Manage Risk Failure Mode Effects Analysis (FMEA) Failure Mode, Effects and Criticality Analysis (FMECA) Risk Probability Number (RPN) Fault Tree Analysis (FTA) Hazard Analysis and Critical Control Points (HACCP) Hazard Operability Analysis (HAZOP) 9

Highest risk the sterile core Personnel Media fills Facility & room Aseptic processing line Daily Sterility Assurance Sterilization processes Process personnel flow material flow layout QA/QC Disinfection practices Deviations & environmental control trends HVAC/ utilities 10 From presentation by Richard L. Friedman, Center for Drug Evaluation & Research

Key Step in Risk-Based Approach - Critical Control Point Identification Causes of Contamination Where are the potential routes of contamination in a sterile or an aseptic process? Detection of Contamination Problem What measurements are most valuable in indicating sterility assurance? Focus on issues of concern Influential factors that determine control of the facility and process Failure to meet cgmp can impact safety or efficacy 11

FMEA Risk Assessment Tool Aligns risks of failure with source of failure Helps determine risk Root causes Likelihood Impact Detection Output of FMEA is a risk priority number (RPN) RPNs input in a simple matrix to help prioritize tasks 12

Overview of RPN Calculation Slide courtesy of Dr. H. Gregg Claycamp (FDA) Severity of Effect 10 9 8 7 6 5 4 3 2 1 S Occurrence Probability 10 9 8 7 6 5 4 3 2 1 O S x O Detection 1 2 3 4 5 6 7 8 9 10 Criticality S x O x D Scoring does not have to be linear. Scoring does not have to be 1-5 or 1-10 SOD or Risk Number (RPN) 13

Risk Values & Risk Matrix - Calculates Criticality, Allows Prioritization Risk values (Probability x Impact) are the same as Criticality (Severity x Probability) in an FMEA analysis Risk matrix allows task prioritization WHO Guideline on QRM. Draft 2010 14

15 Example of Risk Assessment Applied to Filtration

Challenges of Aseptic Processing Drug Product Sterilizatio n Process Sterile DP Container Closure Sterilizatio n Process Sterilizatio n Process Sterile Containe r Sterile Closure Aseptic Processing Sterile Final Product Excipient Component Sterilizatio n Process Sterile Excipient Componen t Multiple sterilization processes optimized for the individual materials Higher potential risk of non-sterile product 16

Filter locations in a generic vaccine formulation / filling suite Vent WFI Blanket / transfer gas CIP Vent Washing s Drying Vial washing Vent IT gas inlet Vent IT gas inlet Clean room utility gas s Depyrogenation API Protection Protectio n Gassing Vent WFI Excipient PrebioburdenSterilizing Sterile filtration 17 Formulation Bioburden & sterile filtration Divide locations into critical, moderately critical and service Helps prioritize resources. Sterile hold tank Stopper washer dryer Autoclave Aseptic filler Freeze dryer

Review & Categorize Filters Site-wide Critical The directly affects product quality Examples: sterile liquid, vent on a sterile hold vessel, Moderately critical The indirectly affects product quality Examples: vent in a grade C area, bioburden reduction Service The does not affect product quality Examples: distribution gas, water pre 18

Filter locations in generic vaccine formulation / filling suite Vent WFI Blanket / transfer gas CIP Vent Washing s Drying Vial washing Vent IT gas inlet Vent IT gas inlet Clean room utility gas s Depyrogenation API Protection Protectio n Gassing Vent WFI Excipient PrebioburdenSterilizing Sterile filtration 19 Formulation Bioburden & sterile filtration Divide locations into critical, moderately critical and service Helps prioritize resources. Sterile hold tank Stopper washer dryer Autoclave Aseptic filler Freeze dryer

Filter Risk Assessment Considerations Fluid classification Dosage form Room classification Location of in the process Contact time Process conditions Fluid pretreatment Filter pretreatment Prior history 20

FMEA (RPN) & Detection Rating for Sterile Processes Use as discussion on detection methods sterility testing is statistical, integrity testing relies on quality, good procedure, qualified tester, etc. Very useful as starting point for discussion on rankings especially occurrence Managing Process Risk Line by Line: Greulich & Hardy Pharm Manufacturing 2007 21 FMEA: A Risk-Based Approach to Sterility Assurance: C. Alexander Pharm Manufacturing 2006 Filter integrity occurrence example: Score 1 = out of the box, Score 3 = at end of total process

Example for a Sterile Filter Issue - From PQRI Final report Event Microorganisms not removed from the product resulting in non-sterile product Severity score = 4 Major: Has a substantial potential to have an adverse effect on the identity, strength, quality, purity or potency of a drug product Frequency score = 3 Likely: Event may occur and/or has occurred in the past Detectability score = 1 Readily Detectable: Can be detected using IT and sterility test Overall Score: 4 * 3 * 1 = 12 NB max score is 64 in this category (i.e. 4 * 4 * 4) 22

Example of Sterile Filter Issue in Facility not Practicing cgmp or QRM Failure Potential S Potential O Current D RPN Mode Effects Causes Controls Non-Integral Filter Non-sterile product 5 Incorrect used 1 Operator compares catalog number to BMR 2 10 5 Unqualified 5 No comparability testing performed 5 125 5 Pre-use IT test not done 5 False post-use IT pass value 5 Unqualified integrity tester 5 Out-of-spec. SIP cycle 5 Poorly maintained housing 4 No pre-use test required on BMR 5 Operator training on IT equipment 3 No tester IOQ & PQ completed 2 Sterilization cycle details on BMR 4 No visual inspection required and noted on equipment log 5 100 4 100 5 75 3 30 5 100 23

3D System Risk Assessment Concept Considers a system s distance from the process stream its location along the process stream the system s complexity Highest score is highest risk This tool is mainly used to assign a risk level to an overall system Excellent for complex systems as part of big picture analysis 24 A 3-D Risk Assessment Model, Journal of Validation Technology [Autumn 2008] pp70-76

Potential Sources of Filter-based Risk

Potential Risk Source - Poor Vendor Qualification Vendor qualification is a cgmp requirement Poor / no qualification can result in Supply issues Inconsistent quality Inconsistent performance Inadequate documentation Poor technical support 26

Potential Risk Source - Poor Equipment Qualification Equipment unable to achieve required accuracy, reproducibility Equipment incapable of operating over required range of conditions Unverifiable data transferred to batch documents and used to release product Poor reliability Inconsistent calibration, preventative maintenance Undocumented or inconsistent change control E.g. Consider an integrity tester 27

Potential Risk Source - Poor Sterile Filter Qualification Categories Flushing Product instability Chemical Compatibility Non-sterile product Integrity failure Product instability Extractables Product instability Product degradation Adsorption Product instability Efficacy below spec. Shelf-life issue Integrity testing Lower retention Non-sterile product Sterilization Non-sterile product Filter damage Bacterial Retention Lower retention Non-sterile product Capacity testing Filter blocks mid-process 28

Eight Filter Validation Elements Retention Integrity Testing Compatibility VMP, QS & Documentation Binding Extractables & Leachables Duty Sterilization Validation must represent worst case process conditions Feed solution Time Pressure Fluid volume Sterilization environment, etc. 29

What Documentation should Support Sterilizing Filtration? Risk analysis based approach to processing and product impact Quality by design GMP? Suitability for duty Adsorption Extractable Integrity testing Bacterial retention Sterilisation process validation Product stability testing Equipment qualification 30

Conclusion Quality risk management (QRM) is part of cgmp and an expected component of a regulated production process Risk is present in all biopharm operations Tools are available to assess risk FMEA process and output allows risk and activity prioritization Sterile and bioburden filtration are integral components in all biopharmaceutical processes Vendor, equipment, qualification is vital to ensure safe, economic and compliant production Sterile filtration qualification is a well-established process Filter categorization makes systems simpler and more robust 31

Some Useful Regulatory References FDA Quality Systems Approach to Pharmaceutical Current Good Manufacturing Practice Regulations Sterile Drug Products Produced by Aseptic Processing - Current Good Manufacturing Practice PICS PE 009-7 GMP Guide (especially Annex 1 and Annex 20) WHO WHO Guideline on Quality Risk Management (Draft Working copy) (2010) WHO Technical Report Series 908, Annex 7 (2001) ICH Q10 Pharmaceutical Quality System Q9 Quality Risk Management PDA TR44 Quality Risk Management for Aseptic Processing TR26 Sterilizing Filtration of Liquids TR40 Sterilising Filtration of Gases PQRI (Product Quality Research Institute) Post Approval Changes for Sterile Products Working Group - Final Report April 19, 2007 32

Useful Definitions Integrity Test - Test to determine the functional performance of a system Validation - Action of proving, in accordance with the principles of Good Manufacturing Practice, that any procedure, process, equipment, material, activity or system actually leads to the expected results. (PICS PE-009 GMP Guide) Critical applications - Where process fluids are in direct contact with sterile final product or critical surfaces of the associated equipment. (PDA TR40) Moderately critical applications - Are those where the ed gas will not be in direct contact with exposed sterile product or surfaces. (PDA TR40) Redundant filtration - A type of serial filtration where a second sterilizing is used as a backup in the event of an integrity failure of the primary sterilizing. (PDA TR26) Serial Filtration - Filtration through two or more s of the same or decreasing pore size one after the other (PDA TR26) Sterilising Filter - a sterile of nominal pore size of 0.22 micron (or less), or with at least equivalent microorganism retaining properties (PICS PE-009 GMP Guide) A sterilizing grade should be validated to reproducibly remove viable microorganisms from the process stream, producing a sterile effluent (FDA) A that reproducibly removes all test microorganisms from the process stream, producing a sterile effluent. (PDA TR26) 33

Thank You for your Attention! Somasundaram.g@merckgroup.com